[3]
One cannot verify unexpected and unpredictable properties of new compounds. (
Pfizer Canada Inc. et al. v. Canada (Minister of Health) et al.
, [2007] 2 F.C.R. 137; 351 N.R. 189; 2006 FCA 214, at para. 24 (
Pfizer v. Ratiopharm
).)